Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Rheumatology|August 18, 1999
A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritisJ Caldwell, R M Gendreau, D Furst, et al.
Bioinformatics (Oxford, England)|January 6, 2007
Oligonucleotide microarray identification of Bacillus anthracis strains using support vector machinesM Doran, D S Raicu, J D Furst, et al.
The American Review of Respiratory Disease|May 1, 1981
Lack of sensitivity of measurements of Vd/Vt at rest and during exercise in detection of hemodynamically significant pulmonary vascular abnormalities in collagen vascular diseaseZ Mohsenifar, D P Tashkin, S E Levy, et al.
International Journal of Immunogenetics|June 20, 2015
HLA class II susceptibility pattern for type 1 diabetes (T1D) in an Iranian populationJ Kiani, M Hajilooi, D Furst, et al.
The Journal of Rheumatology|May 22, 2001
A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis. OMERACT Drug Safety Working PartyJ A Lipani, V Strand, K Johnson, et al.
The Journal of Rheumatology|June 1, 1995
Health status instruments / utilitiesN Bellamy, M Boers, D Felson, et al.
The American Journal of Medicine|July 1, 1983
Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosisR G Ungerer, D P Tashkin, D Furst, et al.
Arthritis and Rheumatism|June 1, 1993
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical TrialsD T Felson, J J Anderson, M Boers, et al.
Arthritis and Rheumatism|June 1, 1995
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisD T Felson, J J Anderson, M Boers, et al.
Lancet (London, England)|January 6, 2000
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupR Maini, E W St Clair, F Breedveld, et al.
Pageof 5